Expert Review of Pharmacoeconomics & Outcomes Research

Papers
(The H4-Index of Expert Review of Pharmacoeconomics & Outcomes Research is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-03-01 to 2025-03-01.)
ArticleCitations
A landscape analysis and discussion of value of gene therapies for sickle cell disease48
Adherence to augmentation therapy for the treatment of major depressive disorder38
How do patients value features of biological medicine in rheumatoid arthritis? A discrete choice experiment28
A retrospective observational analysis of the real-world care pathway of people with hereditary transthyretin amyloidosis with polyneuropathy in Italy23
Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening20
Analysis of prescriptive monitoring regarding the current therapeutic landscape of rheumatoid arthritis: the experience of an Italian local health authority20
The cost-of-illness of multiple sclerosis in Jordan18
The hidden burden of atopic dermatitis in central and Eastern European countries18
Methodological standards for comparative effectiveness research: considerations for evidentiary review for medicare drug price negotiation15
Economic evaluation of interventions to improve medication adherence among patients with chronic diseases: an overview of systematic reviews14
The pharmacoeconomic impact of follitropin alpha biosimilars in IVF therapy in Europe: a report of the literature13
Burden of ischemic heart disease in Spain: incidence, hospital mortality and costs of hospital care13
Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab, and benralizumab added to the standard of care in adults with severe asthma in Colombia12
Economic evaluation of stereotactic radiotherapy and stereotactic radiosurgery technologies in the treatment of cancers: a systematic review12
The implications of cardiac device cybersecurity responsibilities and challenges faced by policymakers, manufacturers, and patients12
0.67340207099915